Systemic delivery of antisense oligonucleotides to drive exon skipping, and restoration of dystrophin expression, has the most promise as a therapeutic for the majority of Duchenne muscular dystrophy (DMD) patients. Similar approaches are also in early stage development for SMA and myotonic dystrophy. A challenge with the exon skipping approach for DMD is the requirement for many distinct drugs targeting different exons. Indeed, exon skipping is being considered by the FDA as an early example of personalized medicine, where drug development is optimized for the specific patient genetic code. This complicates the drug development process, greatly increasing potential cost and time required for diminishing numbers of DMD patients. An alternative approach, used for flu vaccines, is approval 'as a class'. The initial three AO drugs applicable to the greatest number of patients are exons 45, 51, and 53. Once safety and efficacy is proven with these three exon-specific drugs, approval of exon skipping as a class may facilitate drug approvals for less common exons. In this project, we propose a systematic opfimization of AO drugs for exons 45, 51, and 53. Multiple in vitro and in vivo experimental systems will be utilized to validate potency of each drug. Part of the development process for axon 45 is currently funded by a NIH UOl to the PI of this project;this funded program will be extended to patient cell studies from Project 3 and Core C. For exons 51, and 53, the entire drug development process will be funded by the proposed research program. The last aim conducts a 6 month functional efficacy study of the truncated dystrophins in dystrophin-deficient mice lacking exon 52, and will test drugs optimized for both exons 51 and 53.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZAR1-KM)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Children's Research Institute
United States
Zip Code
Sreetama, S C; Takano, T; Nedergaard, M et al. (2016) Injured astrocytes are repaired by Synaptotagmin XI-regulated lysosome exocytosis. Cell Death Differ 23:596-607
Hathout, Yetrib; Seol, Haeri; Han, Meng Hsuan J et al. (2016) Clinical utility of serum biomarkers in Duchenne muscular dystrophy. Clin Proteomics 13:9
Coley, William D; Bogdanik, Laurent; Vila, Maria Candida et al. (2016) Effect of genetic background on the dystrophic phenotype in mdx mice. Hum Mol Genet 25:130-45
Boca, Simina M; Nishida, Maki; Harris, Michael et al. (2016) Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study. PLoS One 11:e0153461
Hathout, Yetrib; Conklin, Laurie S; Seol, Haeri et al. (2016) Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children. Sci Rep 6:31727
Loell, Ingela; Raouf, Joan; Chen, Yi-Wen et al. (2016) Effects on muscle tissue remodeling and lipid metabolism in muscle tissue from adult patients with polymyositis or dermatomyositis treated with immunosuppressive agents. Arthritis Res Ther 18:136
Dillingham, Blythe C; Benny Klimek, Margaret E; Gernapudi, Ramkishore et al. (2015) Inhibition of inflammation with celastrol fails to improve muscle function in dysferlin-deficient A/J mice. J Neurol Sci 356:157-62
Hathout, Yetrib; Brody, Edward; Clemens, Paula R et al. (2015) Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 112:7153-8
Freishtat, R J; Nino, G; Tsegaye, Y et al. (2015) Pharmacologically-induced mitotic synchrony in airway epithelial cells as a mechanism of action of anti-inflammatory drugs. Respir Res 16:132
Echigoya, Yusuke; Aoki, Yoshitsugu; Miskew, Bailey et al. (2015) Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice. Mol Ther Nucleic Acids 4:e225

Showing the most recent 10 out of 33 publications